proqr therapeutics is a leiden, nl based biotech company focused on developments of drugs to treat genetic disorders. based on a novel proprietary technology we discover and develop drugs to change the lives of patients around the world. founded by industry icons and based on ground breaking science we strive to make a meaningful impact. check out our website for vacancies: www.proqr.com
Company profile
Ticker
PRQR
Exchange
Website
CEO
Daniel De Boer
Employees
Location
Fiscal year end
Industry (SIC)
Former names
ProQR Therapeutics B.V.
SEC CIK
PRQR stock data
Latest filings (excl ownership)
6-K
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
19 Apr 24
20-F
2023 FY
Annual report (foreign)
13 Mar 24
6-K
ProQR Announces Year End 2023 Operating and Financial Results
13 Mar 24
6-K
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
15 Feb 24
6-K
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
19 Jan 24
6-K
Current report (foreign)
5 Jan 24
6-K
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
8 Dec 23
6-K
Current report (foreign)
7 Nov 23
6-K
ProQR Therapeutics Provides Update on Ophthalmic Assets
27 Sep 23
6-K
Current report (foreign)
3 Aug 23
Latest ownership filings
SC 13G/A
VAN HERK INVESTMENTS B.V.
14 Feb 24
SC 13G/A
VAN HERK INVESTMENTS B.V.
9 Feb 24
SC 13G
VAN HERK INVESTMENTS B.V.
14 Sep 23
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 23
SC 13G/A
Stichting Aescap Life Sciences
9 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
9 Feb 23
SC 13G/A
GOLDMAN SACHS GROUP INC
8 Feb 23
SC 13G/A
ELI LILLY & Co
23 Dec 22
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
9 May 22
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
52.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 53 |
Opened positions | 9 |
Closed positions | 10 |
Increased positions | 12 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 33.57 bn |
Total shares | 43.00 mm |
Total puts | 13.90 k |
Total calls | 139.50 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
LLY Lilly(Eli) & Co | 13.37 mm | $22.06 mm |
Stichting Aescap 2.0 | 5.34 mm | $0.00 |
Fund Management B.V. Privium | 5.34 mm | $8.66 bn |
Adage Capital Partners GP, L.L.C. | 3.63 mm | $5.87 bn |
Goldman Sachs & Co | 3.30 mm | $13.85 mm |
EcoR1 Capital | 2.98 mm | $4.83 bn |
M28 Capital Management | 1.91 mm | $3.10 bn |
DAFNA Capital Management | 940.58 k | $1.52 bn |
Opaleye Management | 653.00 k | $1.06 bn |
MCQEF Macquarie | 620.00 k | $1.00 bn |
News
ProQR Therapeutics Says It Achieved Successful Defense of New Challenge To Its Axiomer IP Portfolio
19 Apr 24
HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target
14 Mar 24
Chardan Capital Maintains Buy on ProQR Therapeutics, Raises Price Target to $2.5
14 Mar 24
ProQR Therapeutics FY EPS $(0.38) Up From $(0.97) YoY
13 Mar 24
Press releases
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
19 Apr 24
ProQR Announces Year End 2023 Operating and Financial Results
13 Mar 24
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
15 Feb 24